Benchmark analyst Bruce Jackson attributes concerns about China as the cause of yesterday's 6.6% slide in shares of Staar Surgical (STAA), adding that cautious commentary from Align Technology (ALGN) on China may have been a contributing factor. The first quarter is typically a seasonally weak quarter for Staar in China, according to Jackson, who "wouldn't be overly concerned at this juncture" and sees no change to the fundamentals as of today. However, increased volatility seems likely until the scope and duration of the outbreak are fully known, added Jackson, who keeps a Buy rating on Staar shares.

Stifel raised the firm's price target on Align Technology to $400 from $350 and keeps a Buy rating on the shares. Respondents to the firm's survey point to "solid" 2024 year-over-year case volume growth and while Invisalign's share is expected to step down "modestly" year-over-year, new product feedback is upbeat, says the firm, which adds that it has "an upside bias to our 2024 revenue estimate."